| 2024-11-13 | +1.77 % |
|
| 2024-11-11 | -0.38 % |
|
| 2024-11-04 | -3.72 % |
|
| 2024-11-01 | +1.77 % |
|
| 2024-10-31 | -2.17 % |
|
| 2024-10-30 | +0.81 % |
|
| 2024-10-29 | -0.82 % |
|
| 2024-10-28 | +1.53 % |
|
| 2024-10-25 | -0.82 % |
|
| 2024-10-24 | -3.96 % |
|
| 2024-10-23 | -0.27 % |
|
| 2024-10-22 | +0.03 % |
|
| 2024-10-21 | -1.98 % |
|
| 2024-10-18 | +1.19 % |
|
| 2024-10-17 | -1.77 % |
|
| 2024-10-16 | +1.07 % |
|
| 2024-10-15 | -0.13 % |
|
| 2024-10-14 | +1.35 % |
|
| 2024-10-11 | -0.11 % |
|
| 2024-10-10 | +0.06 % |
|
| 2024-10-09 | +1.49 % |
|
| 2024-10-08 | +0.05 % |
|
| 2024-10-07 | -1.45 % |
|
| 2024-10-04 | -0.5 % |
|
| 2024-10-03 | -0.76 % |
|
| 2024-10-02 | -1.01 % |
|
| 2024-10-01 | -0.49 % |
|
| 2024-09-30 | +0.29 % |
|
| 2024-09-27 | -0.03 % |
|
| 2024-09-26 | +1.74 % |
|
| 2024-09-25 | -1.12 % |
|
| 2024-09-24 | +0.05 % |
|
| 2024-09-10 | -0.19 % |
|
| 2024-09-04 | +2.05 % |
|
| 2024-09-03 | +0.04 % |
|
| 2024-08-30 | +0.33 % |
|
| 2024-08-07 | -0.28 % |
|
| 2024-08-06 | +5.99 % |
|
| 2024-08-01 | +1.32 % |
|
| 2024-07-31 | -0.98 % |
|
| 2024-07-25 | +0.61 % |
|
| 2024-07-23 | -0.76 % |
|
| 2024-07-22 | +1.22 % |
|
| 2024-07-18 | -1.55 % |
|
| 2024-07-17 | -0.47 % |
|
| 2024-07-12 | +0.73 % |
|
| 2024-07-08 | +0.27 % |
|
| 2024-07-03 | +0.45 % |
|
| 2024-07-02 | +1.29 % |
|
| 2024-07-01 | -0.45 % |
|
| 2024-06-28 | -1.76 % |
|
| 2024-06-27 | +3.25 % |
|
| 2024-06-26 | +1.74 % |
|
| 2024-06-25 | -2.25 % |
|
| 2024-06-24 | +0.44 % |
|
| 2024-06-21 | +1.73 % |
|
| 2024-06-20 | -0.87 % |
|
| 2024-06-12 | -1.67 % |
- The article discusses Ethic Inc.'s increased stake in Zoetis Inc. (NYSE:ZTS) by 1.3% during the 4th quarter, with other institutional investors also buying and selling shares, leading to Zoetis stock experiencing a decrease of -1.67%, potentially influenced by these transactions and market conditions.
- Summary: Icon Wealth Advisors LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS), institutional investors like Cary Street Partners Investment Advisory LLC and Peak Financial Advisors LLC have also made changes to their positions, while a number of research firms have weighed in on ZTS, giving it a consensus "Buy" rating; despite positive earnings results, ZTS stock experienced a -1.67% decrease likely due to lowered target prices from analyst reports.
Zoetis (ZTS) stock went down likely due to analysts at research firms like HSBC, Stifel Nicolaus, Piper Sandler, and Goldman Sachs dropping their target prices on ZTS, leading to a consensus "Buy" rating with an average target price of $211.75.
|
| 2024-06-10 | +1.08 % |
|
| 2024-06-07 | +0.08 % |
|
| 2024-06-06 | +0.55 % |
- The article discusses Zoetis Inc.'s (ZTS) performance at Stifel's 2024 Jaws & Paws Conference, highlighting the company's ongoing resiliency in the companion animal business and positive growth trends despite modest vet visits. The increase in ZTS stock price is attributed to the company's ability to deliver growth even in challenging environments, its diverse product portfolio, and strong demand in the veterinary space.
- Summary: Zoetis Inc. (ZTS) stock was up by 0.55%, with analysts giving it a consensus "Buy" rating and an average 12-month price target of $211.75, despite recent adjustments in target prices by various research firms. The stock's increase may be attributed to positive quarterly earnings results, with the company reporting higher than expected earnings and revenue for the previous quarter.
Reason for Stock Increase: Zoetis (ZTS) stock likely went up due to the company's strong quarterly earnings report, where they exceeded earnings per share estimates and posted higher revenue. Additionally, positive analyst ratings and a favorable outlook for the company's products and services may have contributed to the stock's increase.
- The article summarizes the discussion between analysts and the CFO of Zoetis at a conference, highlighting Zoetis' strong position as a market leader in the animal health industry, its consistent outperformance of the market, focus on innovation and customer engagement, and the potential for growth in both the companion animal and livestock segments. Zoetis' stock likely went up due to the positive outlook presented during the conference, emphasizing the company's ability to drive growth and maintain resilience in challenging economic conditions.
|
| 2024-06-05 | +2.29 % |
- Summary: Zoetis (ZTS) stock went up by 2.29% last night following the publication of their 2023 Sustainability Report, showcasing their progress in achieving long-term sustainability goals across communities, animals, and the planet through initiatives such as increased volunteer work, grants supporting veterinarians and farmers, renewable energy use, and innovative animal health products. The focus on sustainability and positive impact on various aspects led to an increase in investor confidence and the stock's upward movement.
Reason for Zoetis (ZTS) stock increase: The stock went up likely due to the positive reception and investor confidence generated by Zoetis' 2023 Sustainability Report, demonstrating the company's commitment to sustainability, social responsibility, and impactful initiatives across communities, animals, and the planet, which resonated positively with investors.
- In a summary, the article states that Pomerantz LLP is investigating claims regarding Zoetis Inc. (ZTS) and its drugs Librela and Solensia, which are used to treat arthritis in dogs and cats, but last night the ZTS stock went up by 2.29% possibly due to positive market sentiment or other factors influencing stock prices.
- The article discusses how Rafferty Asset Management LLC reduced its holdings in Zoetis Inc. (ZTS) stock, while other hedge funds made changes to their positions, and an executive vice president sold shares. Zoetis stock went up likely due to better-than-expected earnings, reporting $1.38 EPS for the quarter and revenue growth, leading to a positive outlook by analysts and institutions.
|
| 2024-06-03 | +1.66 % |
|
| 2024-05-31 | +0.07 % |
- Summary: The article discusses why Zoetis (ZTS) stock has the potential for growth despite recent struggles, with resilient healthcare firms such as ZTS, Stryker (SYK), and Eli Lilly (LLY) being considered strong investment options due to solid fundamentals and growth prospects. ZTS stock has shown positive performance after beating earnings estimates and is poised for growth with potential new drugs in the pipeline.
Reasons for Zoetis (ZTS) stock going up:
1. Zoetis has shown resilience with solid fundamentals in the healthcare market.
2. Despite recent stock struggles, ZTS stock has the potential for growth due to opportunities for expansion with new animal healthcare products like Librela and Solensia.
3. Analysts have assigned a Strong Buy rating to ZTS stock, with an average price target suggesting 21% upside potential.
In summary, the positive earnings report and growth prospects for Zoetis (ZTS) stock are key factors driving its recent performance and potential for future gains.
- Summary: The article discusses the importance of Return on Equity (ROE) as a metric for evaluating a company's profitability and managing investors' money, using Zoetis Inc. (NYSE: ZTS) as an example, which has a high ROE of 47%. The stock of Zoetis went up, likely due to its impressive ROE compared to the industry average, although an excessively high debt-to-equity ratio may pose risks for the company in the future.
Reason for Zoetis (ZTS) stock going up: Zoetis stock went up likely due to its high Return on Equity (ROE) of 47%, which indicates the company's ability to efficiently grow its value and generate profits for shareholders compared to industry averages.
|
| 2024-05-30 | -0.8 % |
|
| 2024-05-29 | -0.29 % |
|
| 2024-05-28 | +0.72 % |
|
| 2024-05-24 | -0.49 % |
|
| 2024-05-23 | -0.67 % |
|
| 2024-05-22 | -0.43 % |
|
| 2024-05-21 | -0.92 % |
- Summary: Zoetis (ZTS) stock was down by -0.92% last night, and the article discusses the importance of managing bovine respiratory disease (BRD) in cattle, focusing on prevention strategies such as implementing effective vaccines like Rhinogard IBR and Bovi-Shield MH-One to reduce the incidence of BRD at weaning.
Reason for ZTS Stock Going Down: Zoetis is a pharmaceutical company that produces vaccines for animal health, and fluctuations in their stock price could be influenced by various factors such as market conditions, company performance, industry news, or macroeconomic trends affecting the veterinary and livestock sectors.
- The Zoetis (ZTS) stock went down due to an investigation by Pomerantz LLP into claims of securities fraud or other unlawful business practices by Zoetis and its officers and/or directors, particularly regarding the safety of Zoetis-produced drugs Librela and Solensia used to treat arthritis in pets, which led to concerns and a drop in stock price on April 12, 2024.
- The article is about Zoetis Inc. (ZTS) participating in an upcoming conference, showcasing its commitment to advancing animal care globally; Zoetis stock might have decreased due to various factors like market sentiment, economic conditions, or company-specific news.
|
